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Significant reductions in the extent of acute injury in the CNS can be achieved by exposure
to different preconditioning stimuli, but the duration of the induced protective phenotype
is typically short-lasting, and thus is deemed as limiting its clinical applicability. Extend-
ing the period over which such adaptive epigenetic changes persist – in effect, expanding
conditioning’s “therapeutic window” – would significantly broaden the potential applica-
tions of such a treatment approach in patients. The frequency of the conditioning stimulus
may hold the key. While transient (1–3 days) protection against CNS ischemic injury is well
established preclinically following a single preconditioning stimulus, repetitively presenting
preconditioning stimuli extends the duration of ischemic tolerance by many weeks. More-
over, repetitive intermittent postconditioning enhances post-ischemic recovery metrics and
improves long-term survival. Intermittent conditioning is also efficacious for preventing or
delaying injury in preclinical models of chronic neurodegenerative disease, and for pro-
moting long-lasting functional improvements in a number of other pathologies as well.
Although the detailed mechanisms underlying these protracted kinds of neuroplasticity
remain largely unstudied, accumulating empirical evidence supports the contention that all
of these adaptive phenotypes are epigenetically mediated. Going forward, additional pre-
clinical demonstrations of the ability to induce sustained beneficial phenotypes that reduce
the burden of acute and chronic neurodegeneration, and experimental interrogations of the
regulatory constructs responsible for these epigenetic responses, will accelerate the iden-
tification of not only efficacious but also practical, adaptive epigenetics-based treatments
for individuals with neurological disease.
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STATE OF THE ART
It is now widely established that organisms, tissues, and cells
respond to sublethal stressors by a transient augmentation in
their innate capacity to resist injury. That low doses of a harm-
ful stimulus can promote beneficial responses forms the basis of
hormesis theory (1), but only relatively recently have the concep-
tual and mechanistic connections between conditioning-induced
tolerance and the hormetic response been recognized (2–5). In
any event, seeking to leverage conditioning- or hormesis-based
adaptive responses in patients suffering from acute ischemia, we
remain somewhat stymied by several features of our laboratory
models that seem to preclude easy translation to the clinic.
Significant progress has been made in preclinical models
that advance our understanding of the molecular and genetic
mechanisms underlying ischemic tolerance in the CNS (6–9).
Many unique subcategories of this general phenomenon have
been identified and subject to experimental scrutiny (8). For
example, we recognize two basic phases or therapeutic windows
for conditioning-induced protection: an early “rapid precondi-
tioning” phase that is manifested nearly immediately after the
adaptive stimulus is presented, which is largely dependent on
rapid post-translational protein modifications, and a delayed
preconditioning phase that takes several hours, sometimes days, to
fully develop, resulting from changes in gene expression. We know
that improved outcomes can result if the conditioning stimulus
is applied to another tissue (“remote conditioning”), although its
neural/humoral mechanism remains elusive. We have also learned
that, even when initiated after the injurious event (“postcondition-
ing”), conditioning stimuli can still afford protection. However,
in all of these conditioning paradigms, we have defaulted to the
assumption that the duration of the resultant injury-tolerant state
requires a defined period of time to become established, and,
more importantly, that it cannot be sustained indefinitely. This
latter supposition has hindered, directly or indirectly, the clinical
applicability of this phenomenon, as physicians face the daunting
challenge of how best to pre- or post-condition patients at a well-
defined higher risk for an ischemic event, let alone post-condition
those stroke patients that present in the absence of recognizable
risk factors. Leveraging such innate adaptive responses to treat
chronic neurodegenerative disease seems even more unlikely, if
not impossible.
Against this backdrop, I explore herein the contention that,
as a result of epigenetics-based changes in gene expression, the
duration of injury resistance following a stress stimulus can be
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increased quite significantly based on specific manipulations of
the “dose” of the conditioning stimulus. Further interrogation of
how best to establish protracted therapeutic windows of innate
neuroprotection will provide some of the most valuable oppor-
tunities for multiplying the clinical potential of conditioning to
prevent and treat both acute and chronic neurological disease.
REDEFINING STIMULUS-RESPONSE
Throughout most of its history at both the bench and in the clinic,
the conditioning/tolerance field has evolved based on a funda-
mental, implicit definition of the very phenomenon we have come
to understand: A transient, but robust, reduction in injury from
acute ischemia can be realized if the tissue is preconditioned “X”
hours prior to the lethal ischemic insult. For the aforementioned
delayed phase of conditioning, the words “transient” and “X” in
this definition have been understood to be ~8–48 h, essentially
bookending the “therapeutic window” for treatment. Similarly,
for postconditioning, preclinical protocols typically involve con-
ditioning shortly after the ischemic event, as well as performing
relatively early assessments of efficacy based largely on lesion quan-
tification. Few studies have examined whether the duration of
tolerance resulting from pre- or post-conditioning can be extended
secondary to manipulating the “dose” of the conditioning treat-
ment, or the related possibility that repetitive postconditioning
during recovery can not only reduce injury but concomitantly
enhance one or more long-term stroke recovery metrics; both
of these advances would portend powerful clinical implications.
In dose–response parlance, if the goal is to invoke a protracted
response or prolonged period of tolerance to a given dose of con-
ditioning, and if the given period of tolerance currently appears
time-limited, then a closer examination of the conditioning dose is
required to achieve this desired response. This has not really hap-
pened in any systematic sense; rather, we were quick to adopt the
general assumption that the only type of tolerance is one defined
by a short therapeutic window.
Every stimulus can be defined by at least three parameters:
magnitude, duration, and frequency. Until the advent of postcon-
ditioning by instituting cycles of brief ischemia during early reper-
fusion, the vast majority of preconditioning paradigms for stroke
have historically involved a single stimulus (i.e., frequency= 1) of
a specific duration and magnitude that set into motion tolerance-
signaling cascades; in the field of myocardial ischemia, repetitive
preconditioning treatments have been explored (10), but not for
the purpose of identifying a treatment that extends the duration
of tolerance. Often overlooked is the fact that, like every stimulus,
every response can also be defined by at least two of the same three
parameters: its robustness and its duration. However, the precon-
ditioning field settled quickly on a magnitude-focused, binary def-
inition of tolerance as protection/no protection measured within
~24–72 h of conditioning; little attention has been focused on
whether the duration of a given protective response – again, what
is essentially the therapeutic window for this treatment – could
be extended. The most obvious way to do so involves changes in
stimulus frequency.
In fact, stimulus frequency is critical not only for determining
the duration of the phenotypic change induced but also for its
cumulative ability to promote an adaptive response, in contrast
to the potential impotence of a single exposure or the poten-
tial injury resulting from multiple exposures combined as one
or administered too closely together. Indeed, evidence emerging
not only in the field of conditioning but across other dimensions
of biology as well indicates that the frequency of the presented
stimulus may be the key dose feature with respect to generating
a beneficial, adaptive response instead of a harmful, maladaptive
response (or no response at all). Exercise represents one exam-
ple of benefit-inducing repetitive conditioning (11); moreover,
recent clinical studies support the contention that increasing the
number of short duration/low intensity bouts of exercise may
provide more “advantages” to the cell, tissue, or organism than
fewer exposures that are longer and/or more severe (and thus may
afford no adaptive benefit or even cause injury) (12). As another
example, repetitive intermittent hypoxia, initiated after incom-
plete spinal cord injury, promotes persistent functional recovery
of respiratory and non-respiratory motor systems, as manifested
by protracted improvements in gait performance in both rodents
(13) and humans (14). In the field of psychology, the enhanced
neuronal plasticity that promotes resilience – instead of vulner-
ability – to a number of different stress paradigms is becoming
recognized as uniquely dependent on the frequency of exposure
to the stressor (15–21). The long-term effects of intermittent
fasting, and meal frequency and timing, on health and disease
outcomes (22) represent additional facets of this same concept.
Finally, repeated exposures to stress are also central to encoding a
largely undefined but still well-recognized “resiliency” in medical,
military, and law enforcement personnel and other individuals
needing to perform well in adverse environments.
EXTENDING THE DURATION OF ADAPTIVE CHANGE
With respect to stimulus frequency influencing the duration of the
resultant phenotype, examples can be found in the conditioning
literature that either strongly hint at such a possibility or support
it directly. For example, the therapeutic window for myocardial
ischemic tolerance resulting from a single hypoxic challenge was
extended significantly if intermittent mild hypoxia is used as the
conditioning stimulus (23, 24). Similarly, long-term thalamic atro-
phy following transient focal stroke in mice was attenuated by an
intermittent hypoxic postconditioning stimulus initiated 5 days
after ictus (25). In neonatal (26) and adult rats (27), multi-day
hypoxic postconditioning reduced cerebral injury when the first
challenge was initiated an hour after the severe hypoxic-ischemic
insult. We found that, relative to the <3-days duration of ischemic
tolerance induced in the mouse neural retina by a single hypoxic
preconditioning stimulus, tolerance lasting at least 4 weeks after
the last hypoxic preconditioning treatment can be realized if the
hypoxic preconditioning challenge is repeated six times over a 2-
week period (28). A similar extension of the therapeutic window
(>2 months) for protection against murine cerebral ischemia is
also afforded by a 2-week intermittent hypoxia preconditioning
regimen (29), but only with stochastic increases in the frequency,
duration, and intensity of the hypoxic stimulus relative to that
which was efficacious in protecting against retinal ischemia. This
distinction, and the examples above, not only suggest that tissue-,
cell, age-, and species-dependent hormetic dose–response rela-
tionships may be operative but also suggest that stimulus frequency
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is not a simple concept in and of itself, and variations in the mag-
nitude and duration of a given intermittently presented stimulus,
as well as its temporal pattern, may make the difference between
efficacy, impotence, and harm. The mixed preclinical track-record
reported to date, wherein some repetitive conditioning protocols
promote stroke tolerance, but not necessarily long-lasting stroke
tolerance (30, 31), may be a reflection of this complexity. While
the concept that extended periods of tolerance resulting from
repetitive conditioning can be modeled in neuronal (32) and cere-
bral endothelial cell (33) cultures, the ultimate identification of
a safe and efficacious, intermittent stimulus-based conditioning
protocol – either physiologic or pharmacologic – that provides
consistent, long-lasting protection in patients will prove extremely
challenging in a diverse cross-section of human patients without
reliable biomarker metrics to guide dosing regimens. Clearly, at
this juncture, continued work in animal models is warranted.
Despite the above caveats, because most heart attacks and
strokes are unpredictable, the inherent clinical advantage of post-
conditioning relative to preconditioning still generates consid-
erable translational excitement. Progress might be accelerated if
postconditioning protocols move beyond cyclical interruptions
of early reperfusion to assessments of the benefits accruing from
more protracted, repetitive treatments, and if long-term survival
rates and functional metrics of post-stroke recovery become the
more standard endpoints. Indeed, in cardiac ischemia, repeated
remote postconditioning improved long-term survival relative to
both a single preconditioning challenge and to an even lower fre-
quency of repetitive remote postconditioning (34). Intentionally
delaying the start of the repetitive postconditioning treatment vol-
ley may be prudent, given that, when initiated a week after stroke,
moderate intermittent hypoxia rescued ischemia-induced impair-
ments in learning and memory (35), whereas initiating the same
treatment 1–2 days post-stroke increased mortality (36). Similarly,
the aforementioned study of intermittent hypoxic postcondition-
ing preventing post-ischemic thalamic atrophy was efficacious
when the stimulus volley was initiated 5 days, but not 1 day,
after ictus (25). Predictably, the optimal treatment window will
likely vary depending on the age, species, injury type, and the
postconditioning stimulus employed [including physical rehabili-
tation and exercise (37, 38)]. No matter what the tissue, rigorous,
systematic investigations of multiple postconditioning “dose” reg-
imens/protocols (34, 36, 39) – essentially time-consuming, iter-
ative, titration-directed experiments – will be needed to identify
both the dose and the optimal time after the acute injury to initiate
treatment if this therapeutic approach is ever to be clinically imple-
mented (40, 41). At present, we really know very little about the
frequency of a given postconditioning stimulus needed to activate
innate plasticity mechanisms capable of promoting and sustaining
a neurorecovery-enhancing phenotype. We know less still about
“preconditioning” treatments that effectively “post-condition” the
stroked brain against a second stroke; repetitive stimuli may hold
promise as the ideal treatment approach for this challenge. That
said, some clinical trials of repetitive conditioning have moved
forward empirically, and some have shown efficacy. As examples,
hyperbaric oxygen treatments (5 days/week for 8 weeks) led to sig-
nificant neurological improvements in both stroke (42) and head
trauma (43) patients, even when the treatment was initiated many
months after injury. And intermittent remote postconditioning by
upper limb cuff inflation twice a day for 300 consecutive days
proved effective in reducing the incidence of recurrent stroke
in patients with symptomatic atherosclerotic intracranial arterial
stenosis (44).
CONDITIONING FOR CHRONIC NEUROLOGIC DISEASE
That distinct patterns of “continuous” but intermittent condition-
ing treatments provide protracted periods of protection against
stroke and other acute neurological disorders implies that the slow
and progressive neuronal death that defines neurodegenerative
disease might also be significantly impacted by a similar thera-
peutic strategy. Evidence from the hormesis field that repeated
presentations of low-dose stressors extend beneficial, prevention-,
and/or recovery-promoting effects in preclinical models of more
chronic cardiovascular, immunological, metastatic, and other
non-neurological and non-psychological pathologies, as well as
in human studies (4), supports this contention. Not surprisingly
then, when tested, the intermittent hypoxia protocol that we lever-
aged in mice to extend the duration of tolerance to acute retinal
ischemia (28) also proved efficacious as a preconditioning stim-
ulus against glaucoma, significantly reducing retinal ganglion cell
somal and axonal loss at 3 and 10 weeks of disease in mice (45).
Moreover, significant improvements in these same cell survival
metrics were realized when we postconditioned mice with a repeti-
tive intermittent hypoxia protocol initiated after disease onset (46).
Repetitive postconditioning with brief bouts of retinal ischemia
was also efficacious in reducing retinal neurodegeneration in rat
models of glaucoma (47) and diabetic retinopathy (48). Suggestive
of potential efficacy in Alzheimer’s, intermittent hypoxic post-
conditioning reduced oxidative and nitrosative stress metrics and
improved morphologic and functional (memory) outcomes fol-
lowing intracerebral injections of amyloid beta (49). Although not
widely realized, an extensive number of preclinical and clinical
studies in the Soviet Union, in which an estimated two million
individuals were treated over long periods of time with inter-
mittent hypoxia, document a variety of health-promoting and
injury-resistant outcomes from such treatments, in the absence of
adverse effects (50). Collectively, these findings provide strong sup-
port for the hypothesis that intermittent conditioning during the
progression of chronic neurological disease may provide a means
of both inducing and “holding on” to an adaptive phenotype that
in turn is manifested not only as a reduction in the kinetics of
disease progression but also as improvements in functional status
and long-term survival.
LIFESPAN EFFECTS
As alluded to above, the idea that repetitive stress conditioning
can trigger and possibly maintain long-lasting phenotypic change
in the CNS actually derives strong historical support from the
neuropsychology and behavior fields, which provide rich exam-
ples of sustained plasticity within and across age groups, and ideal
opportunities for considering stress along a negative–positive con-
tinuum, with distress anchoring one end and “eustress” anchoring
the other (51). For instance, when initiated during adulthood,
repeated mild stress exposures lead to persistent decreases in
behavioral disorders and improvements in memory (52, 53). And
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the literature is actually replete with studies documenting adaptive
phenotypes persisting into adulthood as a result of intermittent,
mild stress challenges only experienced by the individual dur-
ing intra-uterine or post-uterine development. This concept was
introduced over 60 years ago based on the serendipitous find-
ings of Levine (54), and is somewhat akin to the immunological
concept of early childhood vaccinations for conferring life-long
protection against disease. As it turns out, most research over the
ensuing decades has focused on documenting illness phenotypes
secondary to child or adolescent stress in an attempt to understand
the origins of psychiatric disease (55). Nevertheless, reflecting yet
another manifestation of “the dose makes the poison” and new
ways of thinking about evolutionary fitness, there are still some
investigations to be found of beneficial adult phenotypes result-
ing from exposing the same individual, when much younger, to a
given stressor and/or exposing their caregiving mothers to stress
(56, 57). Hypoxia-related examples of the former include the find-
ing that postnatal mice exposed from birth to 4 weeks of age to
mild intermittent hypoxia exhibit improved spatial learning and
memory during their adult life (58), and the report that brief
hypoxic challenges during neonate life confer resistance to senes-
cence and better preservation of cognitive function in aged rats
(59). Resilience to stress in adult mice raised by mothers with access
to postpartum exercise (60) is an example of the latter. Intermittent
separations of baby monkeys from their mother may represent a
form of “stress inoculation” that leads to enhanced arousal regula-
tion and resilience of these offspring in later life (15). There is also
evidence that unpredictable, stochastic stress exhibits unique age-
dependent effects, promoting future resilience when experienced
by juvenile animals, but not by adults (61). Given these and other
provocative findings, some have even proposed – for humans –
intentional exposures to intermittent eustress (like mild hypoxia)
during neonatal or adolescent periods as a way to prevent or lessen
future disease burden (62).
EPIGENETICS AS PRIMARY MECHANISM
The molecular basis of the many adaptive responses to repeated
stress highlighted thus far is predictably complex, given the rel-
ative permanence of the resultant phenotype. Many studies have
sought to characterize the beneficial phenotypes, finding evidence
for increased neurogenesis (53), changes in hormonal balance (15,
18), changes in modulators of synaptic plasticity (63, 64), changes
in sodium–calcium exchangers (NCX) (65), and elevated levels
of HIF gene target mRNAs/proteins (52) or other survival fac-
tors (31), to name a few. While identifying these phenotypes is
interesting with respect to understanding how disease resistance
is ultimately manifested, it is epigenetics that deserves attention
as the fundamental mechanism responsible for the long-lasting
responses to repetitive conditioning stimuli, and thus the likely
target of future therapeutics. In brief, epigenetics involves the
regulatory processes – DNA methylation and changes in chro-
matin structure secondary to post-translational histone modi-
fications – that reside “above” the level of genes and control
their readout. During development, epigenetics specifies cell fate
determination and perpetuation, but we now know that these
same mechanisms are engaged throughout the lifespan by “expe-
rience” or “environment,” in all their different forms. Importantly,
considerable evidence indicates that the changes in gene expression
resulting from these stable covalent DNA modifications or epige-
netic “marks” can be long-lasting, and, in some instances, endure
throughout the lifetime of post-mitotic cells; some may even per-
sist through cell division and be transmitted via the germline
to future generations (see below). Thus, epigenetics is really the
biochemically driven interface between nature (genes) and nur-
ture (all manner of environmental and behavioral/psychological
stresses or exposures). Proximal to this interface, so to speak, dis-
tinct features of an experience or a stressor (e.g., frequency, sever-
ity, etc.) that, as alluded to earlier we have only recently begun to
dissect and define with respect to threshold and interactive effects,
dynamically modify the epigenome. Moreover, epigenetic marks
can accumulate over the course of multiple exposures and then act
collectively to determine a new homeostatic phenotypic set-point.
Distally, after encoding molecular memories of these experiences
and exposures, CNS function and behavior is altered secondary
to changes in gene expression, thus impacting one’s vulnerability
or resilience to future stressors/disease (66). In essence, epigenet-
ics is really the “hard-wired” evolutionary response for successful
adaptation to changing natural and social environments. With
the realization that phenotype is fluid, and not rigidly defined
by genotype, it is not an exaggeration to claim that broadening
our understanding of “neuroepigenetics” (67) and its regulation
at both cellular and organismal levels holds incredible promise for
reducing CNS disease burden and enhancing neurological health.
The ischemia-tolerant phenotype resulting from a pre- or post-
conditioning stimulus is, by definition, an epigenetic response,
but only recently have we begun to directly recognize it as such
(68–70). Genomic and proteomic analyses consistently reveal that
the ischemia-tolerant CNS is defined by a broad transcriptional
repression (6, 68, 71) – in effect, the manifestation of an epige-
netically mediated response to the conditioning stimulus. Tests
of the hypothesis that members of the evolutionarily conserved
polycomb protein family – known repressors of gene transcrip-
tion secondary to their ability to posttranslationally modify his-
tones and thus maintain them in an inactive state (72) – may
be causal epigenetic mediators ultimately responsible for estab-
lishing this metabolically downregulated phenotype confirmed
that increases in polycomb group proteins define the “traditional”
ischemia-tolerant CNS (68, 73). Certainly, other transcriptional
regulators of gene repression – such as repressor element-1 silenc-
ing transcription factor (REST) (74) – may also be involved in
orchestrating this response. Whether polycomb and/or REST pro-
teins and/or others participate in mediating the longer periods of
injury resistance induced by repetitive pre- or post-conditioning
stress paradigms has yet to be examined. Additional studies uncov-
ering other epigenetic features of conditioning-induced tolerance
have been forthcoming (75).
A rapidly evolving subfield of epigenetics extends the aforemen-
tioned phenomenon of even life-long phenotypic change within
an individual to the transmission of adaptive or maladaptive phe-
notypes from parents to their offspring. Epigenetic inheritance,
or transgenerational epigenetics, provides a mechanistic founda-
tion for Lamarck’s notion that the effects of environment and/or
experience could be inherited by, and thus benefit, one’s immedi-
ate offspring – known as “soft inheritance” in Lamarck’s day. This
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phenomenon is not inconsistent with Darwinian evolutionary the-
ory, given the selection pressure inherent in preserving adaptive
phenotypic variation if it increases fitness when resources and/or
other environmental stress levels change; but it does carry the
important implication that random DNA mutations are not the
sole driving force of evolution. In transgenerational epigenetics,
gene expression is altered, not genetic inheritance; environment
becomes heredity. At least in theory, this suggests the possibil-
ity of obtaining desired phenotypes in offspring that prevent or
reduce disease burden and/or enhance vitality by therapeutically
manipulating epigenetic regulatory systems in their parents. Con-
ditioning across generations might seem at first blush to represent
an implausible extension of tolerance’s therapeutic window. How-
ever, while the vast majority of preclinical studies have focused
on the germline linking of adverse or dysfunctional behavioral
changes in an individual to life experiences of their parents or
grandparents (76–78), a small number of reports to date provide
convincing examples, in mammals, of the transgenerational per-
sistence of beneficial, epigenetically acquired phenotypes (79–82).
Moreover, there is very intriguing epidemiological evidence that
this occurs in humans (80, 83–85). Obviously, understanding the
mechanistic basis of both potential outcomes portends huge reper-
cussions for evolutionary biology, and will likely change the face
of our understanding of the genetic basis of neurological disease.
CONCLUSION
Despite the discovery of the robustness of endogenous cytopro-
tection almost 25 years ago, the thousands of published preclinical
successes, and even the dozens of efficacious studies in humans,
the time-limited therapeutic window that has inadvertently come
to define conditioning-based responses continues to constrain its
acceptance as a viable therapeutic strategy, even for acute tis-
sue injury. However, given the accumulating evidence supporting
long-lasting, epigenetics-mediated changes in phenotype in the
CNS and other tissues secondary to repetitive stress, perhaps it is
time to shelf the assumption that conditioning-induced tolerance
is “transient,” reevaluate our assumptions about the defining fea-
tures of tolerance, and in so doing open new doors regarding its
full clinical destiny. As scientists and physicians, capturing the abil-
ity to leverage sustained, beneficial phenotypic changes capable of
providing protracted periods of resilience to acute and chronic
neurological injury should be our next collective goal.
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